News

TREMFYA® Empowers Psoriatic Arthritis Patients: New Study Results

TREMFYA® Empowers Psoriatic Arthritis Patients: New Study Results

New Insights on TREMFYA® (guselkumab) for Psoriatic Arthritis

Johnson & Johnson (NYSE: JNJ) released promising data about TREMFYA® in the ongoing battle against active psoriatic arthritis (PsA). This data stems from the Phase 3b APEX study, which highlights TREMFYA’s unique ability to inhibit structural joint damage effectively. This groundbreaking medicine is the first and only IL-23 inhibitor that has shown substantial efficacy in this regard.

Long-Term Benefits of TREMFYA® Treatment

In the APEX study, TREMFYA® treatment significantly reduced the progression of joint damage at Week 24, with results holding steady through Week 48. Observers noted that patients experienced substantial benefits regarding joint health and inflammation. Approximately 50% of patients undergoing TREMFYA® therapy noted a remarkable 50% improvement in their PsA symptoms over this period, emphasizing the treatment's effectiveness.

Study Findings on Joint Damage Inhibition

What makes these results particularly significant is TREMFYA’s two and a half times greater capacity to prevent joint structural deterioration compared to placebo treatments. This remarkable efficacy applies to both dosing regimens of four weeks and eight weeks, reflecting a consistent, robust response in maintaining joint integrity among patients diagnosed with active PsA.

Impact on Patients Switching from Placebo

For patients initially receiving placebo who transitioned to TREMFYA® at Week 24, the findings were impressive. Their rate of radiographic progression decreased dramatically—evidence that even individuals who have experienced ongoing disease can undergo significant improvement after switching to this treatment.

Physician Insights and Recommendations

Dr. Christopher Ritchlin of the University of Rochester Medical Center emphasized the importance of TREMFYA® in the treatment landscape. He stated that chronic joint damage due to psoriatic arthritis can occur rapidly if left without appropriate treatment. The APEX study illustrates that guselkumab can effectively halt this advance, making it a valuable choice for timely intervention.

ACR50 Success Rates and Continuing Safety Profile

TREMFYA® demonstrated a meaningful improvement in American College of Rheumatology (ACR) response criteria, particularly the ACR50 rates from Week 24 to Week 48 among patients taking the medication. The safety profile remained consistent with previous data, confirming that no new safety concerns emerged during the trial.

Significance of Long-Term Data

This data highlights TREMFYA® as the gold standard for IL-23 inhibitors, particularly in treating the 30% of individuals with psoriasis who may develop psoriatic arthritis. Leonard Dragone, a senior executive at Johnson & Johnson, noted that with TREMFYA®, healthcare providers have a proven and effective first-line treatment option for patients coping with this condition.

Understanding Psoriatic Arthritis

Psoriatic arthritis represents a chronic, immune-mediated inflammatory disease characterized by joint pain, swelling, and skin lesions. It can severely impact quality of life, causing fatigue and associated depressive disorders. The symptoms appear typically between ages 30 and 50, although it can develop at any age.

More on TREMFYA®’s Mechanism

TREMFYA® is unique in that it’s designed to inhibit inflammation at its source by blocking IL-23 and binding to CD64, which can drive immune-mediated diseases like PsA. This dual action presents a strong line of defense against chronic inflammation.

Ongoing Commitment and Future Directions

The release of these findings aligns with Johnson & Johnson’s ongoing efforts to enhance scientific understanding and treatment options available for psoriatic arthritis patients. The company's continual investment in research reflects its commitment to proactive health management and finding effective therapeutic solutions.

Frequently Asked Questions

What is TREMFYA® used for?

TREMFYA® (guselkumab) is used for treating adults with active psoriatic arthritis, moderate to severe plaque psoriasis, and various inflammatory bowel diseases.

How does TREMFYA® work?

TREMFYA® blocks IL-23, a cytokine implicated in the inflammation process, thereby helping to control symptoms and prevent joint damage in psoriatic arthritis.

What are common side effects of TREMFYA®?

Patients may experience respiratory tract infections, headaches, injection site reactions, joint pain, and fatigue, though most side effects are manageable.

Is there a specific treatment schedule for TREMFYA®?

TREMFYA® can be administered every four or eight weeks, depending on individual patient needs as determined by a healthcare provider.

Who should avoid using TREMFYA®?

Individuals with a history of serious allergic reactions to guselkumab or any component of the treatment should avoid using TREMFYA®.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Cognito Unveils Phase 3 Results for Alzheimer Treatment

Updated Category News Views 292

Charting New Waters in Alzheimer's Treatment Well, here's one for the books, folks. Cognito Therapeutics just tossed their latest Phase 3 results from their so-called HOPE study into the ring. We're talking about Spectris AD, a non-drug, at-home gizmo that aims to be the next big thing for Alzheimer's. Yeah, the study didn't exactly hit a home run with the primary...

Continue Reading
Graphic Packaging Shakes Up Leadership and Supply Chain

Updated Category News Views 206

New Leadership Takes the Helm at Graphic Packaging What do you do when you want to streamline an operation that spans continents? Well, if you're Graphic Packaging Holding Company (NYSE: GPK), you bring in fresh leadership to serenade the chaos into a well-oiled machine. Starting December 1, 2026, D. Keith Hamilton will be sinking his teeth into North America Mills &...

Continue Reading
Copper Peptides Shine in New Renue Blue Cream

Updated Category News Views 171

Renue By Science's Ambitious Skincare Launch Alright, we've got a big player stepping up in the realm of skincare with a new face cream packed tightly with science-backed goodies. Renue By Science is revamping their game by anchoring their new Renue Blue Face Cream around the star of the moment: copper tripeptide-1, also known as GHK-Cu. This is more than a beauty gloss...

Continue Reading
BWIN Acquisition Under Scrutiny: Shareholders Alerted

Updated Category News Views 118

BWIN Shareholders in the Hot Seat Over Acquisition Ever feel like you're the last one to know when the music stops in this investing dance? Well, if you're holding shares of The Baldwin Insurance Group, Inc. (NASDAQ:BWIN), it's time to put down your coffee and tune in. Levi & Korsinsky, LLP threw a wrench in the works, launching an investigation to see if this Sequence...

Continue Reading
EUBG Faces Tough Third Quarter Amid Challenges

Updated Category News Views 193

What's Happening with EUBG? Entrepreneur Universe Bright Group, better known in the markets as EUBG, is navigating some choppy waters if their recent financial numbers are anything to go by. You'd think companies boasting a digital-focused strategy would be printing money in today's tech-driven world, but EUBG's third quarter of 2026 has a different story to tell. The...

Continue Reading
Lululemon Faces Class Action: Navigating Investor Impact

Updated Category News Views 138

Lululemon's Legal Storm: Understanding the Background If you thought the yoga gear game was all about stretch and flexibility, Lululemon Athletica, Inc (NASDAQ: LULU) just yanked us back to reality. The company finds itself in a legal tangle with its shareholders following a dismal performance report and a subsequent lawsuit. This situation has unfolded like a second-rate...

Continue Reading
Neil deGrasse Tyson Headlines HIMSS27 with Cosmic Insights

Updated Category News Views 237

celebrated science communicator, is set to close out the HIMSS27 conference with a keynote that's bound to leave a lasting impression. It's a fitting intersection of stars and stethoscopes, as the astrophysicist brings his expansive lens to the nitty-gritty of healthcare innovation. Splicing Science with Storytelling Folks, this ain't your standard healthcare gathering....

Continue Reading
Ranger and Smith Unveil Tea-Infused Chocolate Bar

Updated Category News Views 121

Fresh Collaborations in Portland's Culinary Scene Ah, the sweet crossover in Portland's food scene is once again in the spotlight with a new entry that's sure to titillate taste buds. Ranger Chocolate Co. and Steven Smith Teamaker are at it again, rolling out a delectable creation that merges the poetic elegance of tea with the indulgent richness of chocolate. Welcome,...

Continue Reading
equipifi's BNPL Shop: New Ammo for Credit Unions

Updated Category News Views 189

equipifi's 'Shop': The Big Play in Banking Look, here’s the deal—equipifi just lobbed a new grenade into the finance battlefield, arming credit unions and community banks with 'Shop', their own Buy Now, Pay Later (BNPL) platform. The goal? To put them toe-to-toe with the big fintech wolves—something these smaller guys desperately needed. It's a meaty move, no...

Continue Reading
Amdocs Faces a Storm: Investor Alert as Legal Probe Begins

Updated Category News Views 64

Amdocs' Recent Crisis: What Investors Need to Know Lately, it seems Amdocs Limited (NASDAQ: DOX) has found itself knee-deep in a situation that could make seasoned investors cringe. November shone some harsh light on the company's operations, a move that’s attracted attention from Schall, Brown & Schwartz LLP (“SBS”), a name not exactly foreign to shareholder...

Continue Reading

Top 5 Most Recently Viewed Articles

Cobre del Mayo Initiates Exchange Offer for New Notes

Updated Category News Views 154

Cobre del Mayo Launches Exchange Offer Cobre del Mayo, S.A. de C.V. ("CDM") has announced an exciting exchange offer aimed at providing opportunities for Eligible Holders. This initiative involves exchanging all outstanding Senior Secured PIK Toggle Notes due 2030 for new Senior Secured PIK Toggle Notes due in 2032. Understanding the Exchange Offer The exchange offer is...

Continue Reading
Valuable Michael Jordan Card Discovery Shakes Sports Collectors

Updated Category News Views 159

Remarkable Discovery of Michael Jordan Cards An extraordinary find of over 500 valuable Michael Jordan basketball cards has recently taken the sports world by storm. This discovery adds significant excitement to the sports card market, which has seen a resurgence in interest among collectors and enthusiasts alike. How the Collection Was Found The rare cards were unearthed...

Continue Reading
Foxconn Achieves Record Revenue Due to Strong AI Demand

Updated Category News Views 228

Foxconn's record third quarter performance hit the headlines back in 2024, with a staggering revenue of T$1.85 trillion ($57.3 billion). This marked a significant 20.2% surge from the previous year—one for the books, right? It not only eclipsed analyst estimates but also smashed Foxconn's own projections. You know these desks were buzzing after hearing those figures...

Continue Reading
Worlds Inc. Uplists to OTCQB, Enhancing Market Presence and Value

Updated Category News Views 69

Worlds Inc. Uplists to OTCQB for Enhanced Market Visibility Boston, MA — Worlds Inc. (OTCQB: WDDD) has reached an important milestone by moving up from the OTC Pink Market to the OTCQB Venture Market. This transition is set to improve trading visibility and liquidity, effective immediately. New Strategic Opportunities Ahead Thom Kidrin, the CEO of Worlds Inc., shared...

Continue Reading
Mercer International's Strong Q3 Performance and Dividend Update

Updated Category News Views 109

Mercer International Inc. Reports Third Quarter 2024 Results Selected Highlights Operating EBITDA for Q3 rose by 35% to $50.5 million (net loss of $17.6 million), up from $37.5 million (net loss of $26.0 million) year-over-year. Strength noted in softwood pulp markets. Pulp production was affected by unplanned downtime events. Quarterly cash dividend announced at $0.075

Continue Reading